À LA UNE de l'actualité médicale
Despite widespread use of existing secondary prevention therapy, substantial residual risk of recurrent ischemic events after stroke persisted, varying from approximately 25–30% at 5 years [1]. Traditional risk factors do not explain all epidemiologic features of ischemic vascular event, and there is an urgent need for unraveling new therapeutic targets to reduce the residual risk [2].
Inflammation...
Li Jiejie et al.
Journal of Neuroinflammation 2022; 19(1): 131
Lire la suite
Li Jiejie et al.
Journal of Neuroinflammation 2022; 19(1): 131
Lire la suite
Stroke is ranked the third largest contributor to death and disability adjusted life years worldwide [1]. Cognitive impairment and psychiatric symptoms are prevalent in both the acute and chronic phases of stroke [2, 3]. These symptoms can interfere with restoration of daily function and independent living [4], placing emotional and economical burdens on patients, their families, and society [5, 6]....
Nerdal Vilde et al.
BMC Neurology 2022; 22(1): 234
Lire la suite
Nerdal Vilde et al.
BMC Neurology 2022; 22(1): 234
Lire la suite
